Clarus opened lower at $5.19, compared with its previous close of $5.20. In the last trading session, the stock traded between $5.03 and $5.25. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Clarus is now worth
$ 18.29
Resulting in a loss of
$ 81.71 (81.71%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
66.67%
Hold
33.33%
Sell
0%
Markets Today
Today's Change
$-0.04 (-0.71%)
Day High
$5.25
Day Low
$5.03
Day Open
$5.19
Prev Close
$5.20
Volume
2,92,373
1W Return
17.47%
1M Return
46.18%
3M Return
34.95%
6M Return
79.90%
1Y Return
44.62%
Fundamentals
Market Cap ($ Mn)
198
PE Ratio
-
PB Ratio
0.73
PEG Ratio
-
ROE
-20.98%
ROCE
-23.79%
EPS (TTM)
$0.09
Investment Returns
1 Week
17.47%
1 Month
46.18%
3 Months
34.95%
6 Months
79.90%
9 Months
49.65%
Financials
Quarterly
All values in $ Mn
55.2
Jun 25
69.3
Sep 25
65.4
Dec 25
61.9
Mar 26
56.2
Jun 26
71.2
Sep 26
Updates
10Nov
B. Riley Securities raises Clarus price target to $6, maintains Buy rating
B. Riley Securities maintains a Buy rating on Clarus Corporation. Price target raised from $4.50 to $6.00 by analyst Anna Glaessgen. The new target represents a $1.50 increase over the previous estimate.
2 days ago
7Nov
Lake Street maintains Hold on Clarus, lifts price target to $4
Lake Street raised Clarus Corporation's price target to $4 from $3. Analyst Mark Smith maintained a Hold rating on the stock. The revision reflects an updated valuation assessment for the company.
Consolidated gross margin expanded to 41% from 35.1% YoY. FY26 adjusted EBITDA guidance raised to $15-17 million from $12-13 million. Outdoor segment revenue up 12.4%; Adventure down 20.2%. FY26 sales guidance narrowed to $251-255 million, raising the floor.
Clarus delivered strong Q2 results with adjusted EPS of $0.18, beating the $(0.09) estimate by 300%. Sales rose 1.65% YoY to $56.156 million, surpassing the $53.207 million consensus. The turnaround from a $(0.08) loss per share last year highlights improved operational efficiency.
3mo ago
7Aug
Clarus Life Sciences affirms FY26 sales guidance below estimates
Clarus Life Sciences reaffirms FY26 sales guidance of $245.000M-$255.000M, which trails the $251.550M market estimate. The NASDAQ-listed firm maintains its previous outlook, indicating stable but potentially below-consensus revenue expectations for the fiscal year.
3mo ago
7Aug
Clarus Q3 Results: Sales guidance misses $69.196M estimate
Clarus (NASDAQ: CLAR) guided for Q3 sales of $66.000 million-$68.000 million, missing the $69.196 million analyst estimate. The shortfall raises questions about near-term revenue drivers and market conditions affecting the company’s performance.
